Concepts (311)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mitochondrial Diseases | 17 | 2023 | 320 | 5.740 |
Why?
|
| Mitochondrial Myopathies | 4 | 2023 | 47 | 2.430 |
Why?
|
| Oligopeptides | 2 | 2020 | 1189 | 0.910 |
Why?
|
| Fabry Disease | 4 | 2023 | 90 | 0.780 |
Why?
|
| Endothelin-1 | 11 | 2016 | 314 | 0.760 |
Why?
|
| Optic Atrophy, Hereditary, Leber | 1 | 2019 | 46 | 0.670 |
Why?
|
| Oxidative Stress | 4 | 2016 | 3086 | 0.650 |
Why?
|
| Keratoacanthoma | 2 | 2008 | 33 | 0.630 |
Why?
|
| Information Services | 1 | 2019 | 244 | 0.620 |
Why?
|
| Neuromuscular Agents | 1 | 2018 | 134 | 0.550 |
Why?
|
| Fatigue | 2 | 2023 | 1531 | 0.550 |
Why?
|
| Rare Diseases | 1 | 2019 | 553 | 0.480 |
Why?
|
| Nitric Oxide Synthase Type III | 6 | 2016 | 689 | 0.460 |
Why?
|
| Lipopolysaccharides | 7 | 2016 | 2216 | 0.430 |
Why?
|
| Quality of Life | 3 | 2023 | 12804 | 0.420 |
Why?
|
| Vision Disorders | 1 | 2019 | 1058 | 0.410 |
Why?
|
| Leigh Disease | 2 | 2023 | 75 | 0.400 |
Why?
|
| Heart Diseases | 2 | 2022 | 2788 | 0.390 |
Why?
|
| Liver | 8 | 2006 | 7474 | 0.380 |
Why?
|
| DNA, Mitochondrial | 4 | 2020 | 817 | 0.370 |
Why?
|
| Ethanol | 2 | 2008 | 1342 | 0.370 |
Why?
|
| Nitric Oxide Synthase | 4 | 2005 | 916 | 0.370 |
Why?
|
| Heart Ventricles | 1 | 2022 | 3821 | 0.350 |
Why?
|
| Kupffer Cells | 2 | 2006 | 142 | 0.340 |
Why?
|
| MELAS Syndrome | 3 | 2020 | 50 | 0.330 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2008 | 65 | 0.320 |
Why?
|
| Pregnancy Outcome | 1 | 2018 | 2795 | 0.310 |
Why?
|
| S-Adenosylmethionine | 1 | 2008 | 212 | 0.290 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2007 | 96 | 0.290 |
Why?
|
| Endotoxins | 2 | 2006 | 527 | 0.280 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 1622 | 0.280 |
Why?
|
| Health Care Costs | 1 | 2018 | 3209 | 0.260 |
Why?
|
| Eicosanoids | 1 | 2006 | 279 | 0.250 |
Why?
|
| Pregnancy Complications | 1 | 2018 | 2861 | 0.240 |
Why?
|
| Ubiquinone | 2 | 2016 | 188 | 0.240 |
Why?
|
| Double-Blind Method | 4 | 2023 | 12026 | 0.230 |
Why?
|
| Muscle Fatigue | 1 | 2023 | 83 | 0.230 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2023 | 38 | 0.230 |
Why?
|
| Nonmuscle Myosin Type IIB | 1 | 2022 | 20 | 0.220 |
Why?
|
| Diagnosis, Differential | 8 | 2020 | 12959 | 0.210 |
Why?
|
| Endothelial Cells | 4 | 2016 | 3479 | 0.200 |
Why?
|
| Acidosis, Lactic | 2 | 2020 | 142 | 0.200 |
Why?
|
| Neuronal Ceroid-Lipofuscinoses | 2 | 2013 | 142 | 0.200 |
Why?
|
| Mucopolysaccharidoses | 1 | 2021 | 27 | 0.200 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2006 | 1213 | 0.200 |
Why?
|
| Hepatocytes | 1 | 2008 | 1211 | 0.200 |
Why?
|
| Mitochondria | 4 | 2023 | 3520 | 0.200 |
Why?
|
| Ceruloplasmin | 1 | 2020 | 56 | 0.190 |
Why?
|
| Iron Metabolism Disorders | 1 | 2020 | 27 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 11 | 2008 | 8301 | 0.180 |
Why?
|
| Humans | 46 | 2023 | 744343 | 0.180 |
Why?
|
| Societies, Scientific | 1 | 2020 | 220 | 0.170 |
Why?
|
| Triterpenes | 1 | 2020 | 80 | 0.170 |
Why?
|
| Color Vision Defects | 1 | 2019 | 28 | 0.170 |
Why?
|
| Rhabdomyolysis | 1 | 2020 | 150 | 0.170 |
Why?
|
| Muscle Strength | 1 | 2023 | 592 | 0.170 |
Why?
|
| Ophthalmoplegia, Chronic Progressive External | 1 | 2018 | 17 | 0.170 |
Why?
|
| Skin Neoplasms | 2 | 2008 | 5686 | 0.160 |
Why?
|
| Scotoma | 1 | 2019 | 139 | 0.160 |
Why?
|
| Homocystinuria | 1 | 2018 | 67 | 0.150 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2018 | 103 | 0.150 |
Why?
|
| Male | 29 | 2023 | 350118 | 0.140 |
Why?
|
| Endothelium, Vascular | 2 | 2005 | 4456 | 0.140 |
Why?
|
| Orbit | 1 | 2019 | 426 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 5751 | 0.140 |
Why?
|
| Optic Nerve | 1 | 2019 | 554 | 0.130 |
Why?
|
| Genetic Counseling | 1 | 2019 | 600 | 0.130 |
Why?
|
| Kearns-Sayre Syndrome | 1 | 2014 | 2 | 0.130 |
Why?
|
| Endothelins | 2 | 2006 | 138 | 0.130 |
Why?
|
| Carnitine | 1 | 2016 | 246 | 0.130 |
Why?
|
| Superoxides | 1 | 2016 | 387 | 0.130 |
Why?
|
| Gastrointestinal Diseases | 1 | 2023 | 1170 | 0.130 |
Why?
|
| RNA, Transfer, Leu | 1 | 2014 | 9 | 0.130 |
Why?
|
| Stroke | 2 | 2017 | 9981 | 0.130 |
Why?
|
| Optic Atrophies, Hereditary | 1 | 2014 | 27 | 0.130 |
Why?
|
| Rats | 11 | 2008 | 24260 | 0.130 |
Why?
|
| Caveolins | 2 | 2005 | 104 | 0.130 |
Why?
|
| Homocysteine | 1 | 2018 | 647 | 0.120 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 2029 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2006 | 534 | 0.120 |
Why?
|
| Diabetes Insipidus | 1 | 2014 | 151 | 0.120 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 1405 | 0.120 |
Why?
|
| Enzyme Replacement Therapy | 3 | 2022 | 78 | 0.120 |
Why?
|
| Dietary Supplements | 2 | 2016 | 3297 | 0.120 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2018 | 518 | 0.110 |
Why?
|
| Standard of Care | 1 | 2017 | 564 | 0.110 |
Why?
|
| Female | 19 | 2023 | 380194 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 10943 | 0.110 |
Why?
|
| Ataxia | 1 | 2014 | 304 | 0.110 |
Why?
|
| Hydrogen Peroxide | 2 | 2006 | 731 | 0.110 |
Why?
|
| Hearing Loss, Sensorineural | 2 | 2017 | 770 | 0.100 |
Why?
|
| Neurodegenerative Diseases | 1 | 2020 | 1061 | 0.100 |
Why?
|
| Muscle Weakness | 1 | 2014 | 413 | 0.100 |
Why?
|
| Phosphorylation | 4 | 2006 | 8436 | 0.100 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 1071 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2006 | 4751 | 0.100 |
Why?
|
| Liver Circulation | 3 | 2005 | 164 | 0.100 |
Why?
|
| Adult | 12 | 2023 | 214055 | 0.090 |
Why?
|
| Medicine | 1 | 2019 | 946 | 0.090 |
Why?
|
| Visual Acuity | 1 | 2019 | 2530 | 0.090 |
Why?
|
| Disease Models, Animal | 2 | 2008 | 18029 | 0.090 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 1790 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2020 | 4328 | 0.090 |
Why?
|
| Patients | 1 | 2016 | 900 | 0.090 |
Why?
|
| Emotions | 1 | 2021 | 2661 | 0.090 |
Why?
|
| Adolescent | 6 | 2021 | 85781 | 0.090 |
Why?
|
| Genetic Association Studies | 1 | 2019 | 2703 | 0.090 |
Why?
|
| Potassium Channels | 1 | 2012 | 563 | 0.090 |
Why?
|
| Middle Aged | 10 | 2023 | 213383 | 0.080 |
Why?
|
| Blotting, Western | 3 | 2005 | 5179 | 0.080 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2010 | 85 | 0.080 |
Why?
|
| Cheek | 1 | 2008 | 63 | 0.080 |
Why?
|
| Disease Management | 2 | 2017 | 2459 | 0.080 |
Why?
|
| Mutation | 4 | 2020 | 29786 | 0.080 |
Why?
|
| Brain | 4 | 2020 | 26385 | 0.080 |
Why?
|
| Retina | 1 | 2019 | 2616 | 0.080 |
Why?
|
| Immunity | 1 | 2014 | 1012 | 0.080 |
Why?
|
| Seizures | 2 | 2018 | 2859 | 0.080 |
Why?
|
| Nutritional Status | 1 | 2016 | 1609 | 0.080 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2018 | 1414 | 0.080 |
Why?
|
| Vitamins | 1 | 2016 | 1622 | 0.080 |
Why?
|
| Pemphigus | 1 | 2008 | 103 | 0.080 |
Why?
|
| Treatment Outcome | 5 | 2023 | 63114 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2016 | 1253 | 0.080 |
Why?
|
| Data Collection | 1 | 2017 | 3341 | 0.080 |
Why?
|
| Caveolin 1 | 2 | 2006 | 263 | 0.070 |
Why?
|
| RNA | 3 | 2005 | 2749 | 0.070 |
Why?
|
| Liver Function Tests | 1 | 2008 | 528 | 0.070 |
Why?
|
| Sulfonamides | 2 | 2006 | 1938 | 0.070 |
Why?
|
| Alanine Transaminase | 2 | 2006 | 592 | 0.070 |
Why?
|
| United States | 3 | 2019 | 69872 | 0.070 |
Why?
|
| Immunoglobulin A | 1 | 2010 | 992 | 0.070 |
Why?
|
| Oxidants | 1 | 2006 | 164 | 0.070 |
Why?
|
| Liver Cirrhosis, Experimental | 1 | 2006 | 32 | 0.070 |
Why?
|
| DNA Copy Number Variations | 1 | 2014 | 1941 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 3336 | 0.070 |
Why?
|
| Young Adult | 4 | 2021 | 56430 | 0.070 |
Why?
|
| Phospholipases A | 1 | 2006 | 216 | 0.070 |
Why?
|
| Immunoprecipitation | 2 | 2005 | 905 | 0.070 |
Why?
|
| Receptor, Endothelin B | 1 | 2005 | 41 | 0.070 |
Why?
|
| Microcirculation | 3 | 2005 | 1286 | 0.070 |
Why?
|
| Free Radicals | 1 | 2005 | 237 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2020 | 6544 | 0.060 |
Why?
|
| Thromboxane A2 | 1 | 2005 | 92 | 0.060 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2006 | 137 | 0.060 |
Why?
|
| Anxiety | 1 | 2019 | 4297 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2016 | 2149 | 0.060 |
Why?
|
| Threonine | 1 | 2005 | 279 | 0.060 |
Why?
|
| Child | 6 | 2023 | 77709 | 0.060 |
Why?
|
| Multiple Sclerosis | 1 | 2018 | 3079 | 0.060 |
Why?
|
| Hepatitis | 1 | 2005 | 227 | 0.060 |
Why?
|
| Child, Preschool | 5 | 2018 | 41006 | 0.060 |
Why?
|
| Endotoxemia | 1 | 2005 | 207 | 0.060 |
Why?
|
| alpha-Galactosidase | 1 | 2022 | 57 | 0.050 |
Why?
|
| Graft Rejection | 1 | 2016 | 4397 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2020 | 10180 | 0.050 |
Why?
|
| Nitric Oxide | 2 | 2016 | 2132 | 0.050 |
Why?
|
| Infant | 4 | 2018 | 35136 | 0.050 |
Why?
|
| Parents | 1 | 2016 | 3407 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2006 | 3701 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 17446 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 1060 | 0.050 |
Why?
|
| Phenotype | 4 | 2023 | 16365 | 0.050 |
Why?
|
| Penetrance | 1 | 2023 | 381 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2019 | 15540 | 0.050 |
Why?
|
| Fibrosis | 1 | 2008 | 2029 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2005 | 1792 | 0.050 |
Why?
|
| Necrosis | 1 | 2005 | 1643 | 0.050 |
Why?
|
| Biomedical Research | 1 | 2017 | 3309 | 0.050 |
Why?
|
| Research Design | 1 | 2017 | 5987 | 0.050 |
Why?
|
| Syndrome | 1 | 2007 | 3251 | 0.050 |
Why?
|
| Chelation Therapy | 1 | 2020 | 67 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2018 | 77449 | 0.050 |
Why?
|
| Pain | 1 | 2016 | 4986 | 0.050 |
Why?
|
| Myosin Heavy Chains | 1 | 2022 | 414 | 0.050 |
Why?
|
| Animals | 13 | 2012 | 168757 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 4933 | 0.050 |
Why?
|
| Genome, Mitochondrial | 1 | 2020 | 71 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2020 | 35421 | 0.040 |
Why?
|
| Depression | 1 | 2019 | 7766 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2020 | 121 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2008 | 1889 | 0.040 |
Why?
|
| Constipation | 1 | 2023 | 546 | 0.040 |
Why?
|
| Decision Trees | 1 | 2020 | 506 | 0.040 |
Why?
|
| Unconsciousness | 1 | 2020 | 263 | 0.040 |
Why?
|
| Cilia | 1 | 2022 | 466 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2018 | 25625 | 0.040 |
Why?
|
| Cell Survival | 2 | 2005 | 5882 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2006 | 13033 | 0.040 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2006 | 1990 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2008 | 2925 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2005 | 3002 | 0.040 |
Why?
|
| Ferritins | 1 | 2020 | 590 | 0.040 |
Why?
|
| Autoimmune Diseases | 1 | 2010 | 2133 | 0.040 |
Why?
|
| Aged | 2 | 2022 | 163280 | 0.040 |
Why?
|
| Hedgehog Proteins | 1 | 2022 | 783 | 0.040 |
Why?
|
| Genes, Mitochondrial | 1 | 2017 | 61 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 377 | 0.040 |
Why?
|
| Siblings | 1 | 2021 | 854 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 778 | 0.040 |
Why?
|
| Blood Flow Velocity | 3 | 2005 | 1423 | 0.040 |
Why?
|
| Reference Standards | 1 | 2020 | 1025 | 0.040 |
Why?
|
| Biopsy | 1 | 2008 | 6756 | 0.040 |
Why?
|
| Pregnancy | 1 | 2018 | 29144 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2006 | 2038 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2022 | 1063 | 0.030 |
Why?
|
| Marfan Syndrome | 1 | 2018 | 240 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 4851 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 53288 | 0.030 |
Why?
|
| Actins | 1 | 2022 | 2121 | 0.030 |
Why?
|
| Body Weight | 1 | 2005 | 4669 | 0.030 |
Why?
|
| Genotype | 2 | 2023 | 12951 | 0.030 |
Why?
|
| Lactic Acid | 1 | 2020 | 1133 | 0.030 |
Why?
|
| Microscopy, Video | 2 | 2005 | 245 | 0.030 |
Why?
|
| Drug Design | 1 | 2020 | 1076 | 0.030 |
Why?
|
| Internationality | 1 | 2020 | 1003 | 0.030 |
Why?
|
| Haplotypes | 1 | 2020 | 2779 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2006 | 2529 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2016 | 597 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2006 | 19229 | 0.030 |
Why?
|
| Ganglia, Spinal | 1 | 2016 | 519 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2020 | 1783 | 0.030 |
Why?
|
| Lymphocyte Subsets | 1 | 2014 | 315 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 1836 | 0.030 |
Why?
|
| Brain Edema | 1 | 2018 | 617 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 3966 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2016 | 365 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1850 | 0.030 |
Why?
|
| Models, Biological | 2 | 2006 | 9583 | 0.030 |
Why?
|
| Exercise Test | 1 | 2020 | 2074 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 11366 | 0.030 |
Why?
|
| Consensus | 1 | 2020 | 2959 | 0.020 |
Why?
|
| Perfusion | 2 | 2005 | 1360 | 0.020 |
Why?
|
| Tunisia | 1 | 2010 | 33 | 0.020 |
Why?
|
| Fluorescent Antibody Technique, Direct | 1 | 2010 | 69 | 0.020 |
Why?
|
| Dapsone | 1 | 2010 | 54 | 0.020 |
Why?
|
| Erythromycin | 1 | 2010 | 120 | 0.020 |
Why?
|
| Caregivers | 1 | 2021 | 2094 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3952 | 0.020 |
Why?
|
| Time Factors | 3 | 2005 | 40075 | 0.020 |
Why?
|
| Internet | 1 | 2021 | 3064 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 2077 | 0.020 |
Why?
|
| Heart Rate | 1 | 2020 | 4091 | 0.020 |
Why?
|
| Complement Activation | 1 | 2010 | 453 | 0.020 |
Why?
|
| Prednisolone | 1 | 2008 | 334 | 0.020 |
Why?
|
| Ubiquitin | 1 | 2012 | 852 | 0.020 |
Why?
|
| Registries | 1 | 2022 | 8089 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2016 | 3420 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 2282 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2019 | 3444 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2012 | 1338 | 0.020 |
Why?
|
| Erythrocytes | 2 | 2005 | 2455 | 0.020 |
Why?
|
| Thromboxane-A Synthase | 1 | 2005 | 34 | 0.020 |
Why?
|
| Receptors, Thromboxane | 1 | 2005 | 31 | 0.020 |
Why?
|
| Portal System | 1 | 2005 | 52 | 0.020 |
Why?
|
| Prednisone | 1 | 2010 | 1574 | 0.020 |
Why?
|
| Portal Pressure | 1 | 2005 | 62 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2005 | 225 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 19905 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 2016 | 2119 | 0.020 |
Why?
|
| Migraine Disorders | 1 | 2017 | 1620 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 4644 | 0.020 |
Why?
|
| Life Style | 1 | 2016 | 3835 | 0.020 |
Why?
|
| Benzofurans | 1 | 2005 | 140 | 0.020 |
Why?
|
| Comorbidity | 1 | 2018 | 10388 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 2386 | 0.010 |
Why?
|
| Fractures, Closed | 1 | 2004 | 88 | 0.010 |
Why?
|
| Calmodulin | 1 | 2004 | 209 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2006 | 611 | 0.010 |
Why?
|
| Exercise | 1 | 2020 | 5615 | 0.010 |
Why?
|
| Hydrazines | 1 | 2005 | 226 | 0.010 |
Why?
|
| Automation | 1 | 2005 | 584 | 0.010 |
Why?
|
| HEK293 Cells | 1 | 2012 | 4204 | 0.010 |
Why?
|
| Catalysis | 1 | 2004 | 761 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2016 | 3110 | 0.010 |
Why?
|
| Fracture Healing | 1 | 2005 | 427 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 7279 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 4560 | 0.010 |
Why?
|
| Vasoconstriction | 1 | 2005 | 597 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 23403 | 0.010 |
Why?
|
| Feedback | 1 | 2006 | 795 | 0.010 |
Why?
|
| Cell Line | 1 | 2016 | 15997 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 4931 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12788 | 0.010 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2005 | 546 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2012 | 21827 | 0.010 |
Why?
|
| DNA Primers | 1 | 2006 | 2892 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 2016 | 4251 | 0.010 |
Why?
|
| Gadolinium | 1 | 2005 | 952 | 0.010 |
Why?
|
| Protein Transport | 1 | 2005 | 1988 | 0.010 |
Why?
|
| Femur | 1 | 2005 | 1297 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2006 | 20822 | 0.010 |
Why?
|
| Cell Division | 1 | 2006 | 4568 | 0.010 |
Why?
|
| Kinetics | 1 | 2005 | 6473 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 6386 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2005 | 1917 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2004 | 2699 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 2046 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2005 | 3748 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 20129 | 0.010 |
Why?
|
| Wound Healing | 1 | 2005 | 2785 | 0.010 |
Why?
|
| Skin | 1 | 2006 | 4364 | 0.010 |
Why?
|
| Mice | 2 | 2012 | 81183 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 4409 | 0.010 |
Why?
|
| Protein Binding | 1 | 2004 | 9386 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2004 | 2400 | 0.010 |
Why?
|
| Age Factors | 1 | 2008 | 18370 | 0.010 |
Why?
|
| Sepsis | 1 | 2005 | 2593 | 0.010 |
Why?
|
| Risk Factors | 1 | 2016 | 72290 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 8949 | 0.010 |
Why?
|
| Inflammation | 1 | 2005 | 10638 | 0.000 |
Why?
|
Concepts
(311)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(40)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_